Rhinomed Limited, a medical technology company, researches, develops, and commercializes consumer and medical devices. The company identifies, acquires, and commercializes late stage therapeutic delivery technologies. It markets Turbine, a nasal dilator designed to assist to breathe easier during aerobic exercise; and Mute, a nasal dilator designed to enhance sleep quality by breathing more and snoring less. The company also develops Breathing Space Health that comprises of a range of wellness programs designed to help people get to sleep. In addition, it develops Sleep Apnea, a clinical trial solution to mild and moderate sleep apnea; creates drug delivery platform for delivering medication into the nose in an inhaled form or via a trans-dermal or trans-mucosal method; and researches and develops current programs focuses on olfactory pathway and wearable technology. The company sells its products through wholesalers, retail stores, and clinics, as well as online in the United States, Canada, the United Kingdom, Taiwan, Australia, and New Zealand. It serves clinicians and health care organizations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+61-3-84160900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.35 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Rhinomed (ASX:RNO) Frequently Asked Questions
What is Rhinomed's stock symbol?
Rhinomed trades on the ASX under the ticker symbol "RNO."
How were Rhinomed's earnings last quarter?
Rhinomed Ltd (ASX:RNO) issued its quarterly earnings data on Thursday, February, 28th. The company reported ($0.02) earnings per share (EPS) for the quarter. View Rhinomed's Earnings History.
Has Rhinomed been receiving favorable news coverage?
News coverage about RNO stock has trended somewhat negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Rhinomed earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Rhinomed.
Who are some of Rhinomed's key competitors?
Some companies that are related to Rhinomed include Ampio Pharmaceuticals (AMPE), Circassia Pharmaceuticals (CIR), Equillium (EQ), Oncolytics Biotech (ONC), Botanix Pharmaceuticals (BOT), Biotron (BIT), Oxford Biodynamics (OBD), Sirona Biochem (SBM), Orgenesis (ORGS), Orthocell (OCC), Novacyt (NCYT), Acasti Pharma (ACST), Pediapharm (PDP), Medlab Clinical (MDC) and Verona Pharma (VRP).
Who are Rhinomed's key executives?
Rhinomed's management team includes the folowing people:
- Mr. Michael Johnson, CEO, MD & Director
- Mr. Sean Slattery, Chief Financial Officer
- Mr. Phillip Allen Hains, Company Sec.
What is Rhinomed's stock price today?
One share of RNO stock can currently be purchased for approximately A$0.16.
How big of a company is Rhinomed?
What is Rhinomed's official website?
How can I contact Rhinomed?
Rhinomed's mailing address is 97 Green St, RICHMOND, VIC 3121, Australia. The company can be reached via phone at +61-3-84160900.
MarketBeat Community Rating for Rhinomed (ASX RNO)
MarketBeat's community ratings are surveys of what our community members think about Rhinomed and other stocks. Vote "Outperform" if you believe RNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
